Recently,OYMotion Technology Co., Ltd. (hereinafter referred to as "OYMotion") announced the completion of a nearly RMB 100 million Series B++ financing round.This round of financing was jointly invested by Infiniti Capital, Zhejiang Development Asset Management Co., Ltd. (under Zhejiang Provincial State-owned Capital Operation Co., Ltd.), and Vantage Capital.，Krypton Agent Capital Serves as Long-term Financial Advisor. This follows the completion of OYMotion's B+ round of financing at the end of 2024, inA new round of financing with another quick closing within 3 months, fully showcasing OYMotion's current strong development momentum and high market recognition.

This round of financing will inject strong momentum into OYMotion, assisting the company in achieving leapfrog development in multiple key areas.The funds will be mainly used to accelerate continuous R&D breakthroughs in the dexterous hand technology field, promote the launch of a new generation of dexterous hand products, and expedite the market release of finger joint exoskeleton robots. Meanwhile,Establish an internationally leading standardized production system, optimize production processes, and achieve a 100% increase in annual production capacity.Moreover, OYMotion will further advance its global market layout, providing higher quality and more efficient solutions to customers worldwide.

Zhuhai Greater Bay Area · Core Production and Manufacturing Base

In 2015, OYMotion Technology Co., Ltd. was officially established in Shanghai's Zhangjiang High-Tech Park. As one of the few innovative companies in China that simultaneously masters two core underlying technologies—brain-computer interface and robotics,The company has always focused on the intersection of brain science and robotics, successfully building a "neural interface-robot-AI algorithm"三位一体 self-developed platform.After nearly a decade of technical沉淀, OYMotion has developed multiple innovative products that combine technological leadership with commercial feasibility, and their performance and cost-effectiveness have gained widespread recognition in the global market.

In the cutting-edge field of embodied robotics, OYMotion's first dexterous hand product has already served multiple clients in the main robot sector and has been widely praised. On one hand,As one of the most important upstream solutions in the field of ontological robotics, the dexterous hand has always been highly anticipated within the industry. On the other hand, as a representative product of precision intelligent manufacturing, the dexterous hand faces high technical barriers, complex craftsmanship challenges, and stringent system requirements.Therefore, in the dexterous hand industry, there has always been an impossible triangle, which makes it difficult to balance the three requirements of "cost + system parameters + system stability."

OYMotion is the earliest team in China that has focused on the research of robotic hands. Since 2017, it has completed dozens of iterations and successfully promoted the implementation of robotic hands in various scenarios, such as intelligent bionic hands integrated with neural interfaces (EMG) for amputees, several dexterous hand products for embodied intelligence customers, and finger joint exoskeleton robot products for people with hand dysfunction.

OYMotion ROH-A001 Dexterous Hand

OYMotion's Dexterous Hand Application in the Field of Embodied Robotics

As one of the few manufacturers currently on the market with both batch production experience and batch delivery capabilities, OYMotion has achieved the impossible triangle by setting up multi-scenario SKUs, making it an important player in the first tier of dexterous hand technology. Currently,OYMotion is continuously making efforts in product innovation. The new generation of dexterous hand, ROH-AP001, will have tactile and pressure sensing capabilities, and is expected to be officially launched in the market soon.

OYMotion ROH-AP001 Dexterous Hand

In the field of brain science, OYMotion has developed a medical-grade neuro-interaction software and hardware integrated infrastructure platform based on its self-developed brain/muscle-computer interface technology.Currently, more than 80 patents have been obtained.Including the brain-computer interface OB series, the intelligent bionic hand OHand™ series, the neurorehabilitation exoskeleton ORF series, and many other products.Since its launch in 2020, the OHand™ intelligent bionic hand has quickly captured market share from imported products due to its cutting-edge technology and exceptional cost-performance ratio. In 2023, the OHand™ bionic hand successively obtained FDA/CE certifications and received the U.S. PDAC insurance reimbursement code last year. It has taken the lead in overseas commercialization across multiple countries and regions, including the United States, the Middle East, Russia, Ukraine, and India. OYMotion's bionic hand has become a hallmark of "Made in China."

OYMotion Intelligent EEG Machine OB3000

OYMotion Intelligent Bionic Hand OHand™

OYMotion Completes Two Rounds of Financing in a Short Period, Marking an Important Milestone in the Company's Development.Standing at a new starting point, OYMotion will adhere to its original aspiration, supported by capital power, driven by technological innovation, and oriented towards market demand, continuously forging ahead and scaling new heights.

OYMotion Participates in the 137th Canton Fair Onsite

OYMotion's Booth at the Canton Fair on CCTV Live Broadcast

OYMotion Founder Hua Liang Ni stated: Thank you to our new and existing shareholders for their trust and continued support. Completing two rounds of financing in just a few months is both an acknowledgment from the shareholders and a testament to the company's strong growth potential.After the completion of this round of financing, the OYMotion team will deepen cooperation with industry partners with a more open attitude, jointly promote the industrialization process of brain science and the robotics industry, and strive to become a leading global technology enterprise.

Infinity Capital stated：Infinity Capital has long been highly focused on emerging industries that integrate healthcare, robotics, and AI, represented by brain-computer interfaces and embodied intelligence.As a leading company in this field, OYMotion has taken the lead in exploring practical application scenarios such as intelligent bionic hands, thanks to its profound strategic insight and engineering capabilities. This not only brings good news to a wide range of disadvantaged groups but also provides an important carrier and underlying technology for the development of new quality productive forces. We are very pleased to be a fellow traveler of OYMotion, and we look forward to helping it reach new heights through this investment.

About Infiniti Capital

Infinity Capital Management Co., Ltd. ("Infinity Capital" for short) is an equity investment platform under Huafa Group, a leading state-owned enterprise in Zhuhai and part of the top 500 enterprises in China. It is also the core business entity of Infinity Group, a well-known overseas investment management institution. The company primarily operates domestic RMB fund businesses and cross-border investment businesses, with operations spanning more than 10 cities both domestically and internationally. It has formed five major business segments: Greater Healthcare, East China, South China, Southwest China, and Hong Kong & Overseas Regions. Key investments have been made in fields such as new energy, integrated circuits, artificial intelligence, quantum technology, healthcare and life sciences, advanced manufacturing, and new materials. In recent years, the company's investment performance has continued to grow steadily, with successful IPOs including projects such as Yongsheng Medical (01612.HK), Catalent (002821.SZ), Huati Technology (603679.SH), Liancheng Precision (002921.SZ), Lihu Lake Co., Ltd. (300694.SZ), Lanjian Intelligence (688557.SH), New Glory (688663.SH), HaiChuang Pharma (688302.SH), Chuangyao Technology (688259.SH), Silinjie (688115.SH), Laikang Medicine (2105.HK), and Zhirui Co., Ltd. (301587.SZ). Additionally, Hongtu Separator and IOPtima were acquired by listed companies Jingu Crown (300510.SZ) and Kanghong Pharmaceuticals (002773.SZ), respectively.

Zhejiang Development Asset Management Co., Ltd. stated:OYMotion Focuses on the Cross-Innovation of Brain Science and Robotics, Leading the First Tier of the Dexterous Hand Industry in China. This investment is a significant step by Development Asset Company to promote the integration and innovation of cutting-edge technologies like brain-inspired intelligence with robotics, driving the collaborative upgrading of China's embodied intelligence industry chain.Subsequently, under the guidance of the Yangtze River Delta Integration Strategy, Development Asset Company will leverage the synergies between Shanghai and Zhejiang, utilize their complementary functions, and continuously provide diversified post-investment empowerment support to enterprises. The company will focus on strategic investments and capital operations, supporting OYMotion in becoming a leading enterprise in core components for embodied intelligence.

About Zhejiang Development Asset Management Co., Ltd.

Zhejiang Development Asset Management Co., Ltd. adheres to the mission of "serving major strategies, serving the real economy, and serving state-owned enterprises," and is committed to "participating in all types of capital market businesses and providing comprehensive services for capital operation projects of high-quality listed companies within the province." Its main focus includes private placements, strategic placements, mergers and acquisitions, restructuring, private securities, and other primary and secondary market businesses, as well as mature equity investments in niche markets. The company continuously optimizes its investment layout and enhances quality and efficiency. By the end of 2024, the company's total assets reached 2.66 billion yuan, with over 130 investment projects totaling more than 6.3 billion yuan in investment. Among these, it has supported the transformation and development of more than 50 listed enterprises and nurtured nearly 80 start-up companies, helping them go public on domestic and overseas capital markets.

Womeida Capital stated:Driven by the global wave of intelligent transformation in manufacturing and breakthroughs in artificial intelligence technology, the smart manufacturing and robotics industries are poised for explosive growth opportunities. OYMotion, leveraging its technical expertise in electromyographic signal processing and bionic hand development, is deeply expanding into vertical scenarios within rehabilitation medicine and has established a robust business foundation.At the same time, the company has further leveraged its outstanding capabilities in supply chain integration and commercial execution to strategically enter the embodied intelligence robotics field, forming a multi-driven business landscape. As a long-term value investor, Walden Capital looks forward to utilizing its industry advantages to move forward alongside OYMotion Technology, continuously injecting momentum into the innovative development of the industry.

About Womeida Capital

Womeida Capital is a new industrial capital focusing on healthcare, hard technology, and consumer-related fields, with investment stages covering the entire lifecycle of enterprises. The company has a deep understanding of the development and operation rules of local enterprises and possesses profound industry knowledge, having completed investments in several outstanding companies.